🎉 Exciting News Alert 🎉 We’ve been shortlisted for Best CDMO at the 11th World ADC Awards, honoring the very best in antibody-drug conjugate development. We extend our heartfelt gratitude to the World ADC Event Series and the global ADC community for your support. #WorldADC #LonzaBioconjugates #LonzaDPS
Info
At Lonza, we enable A Healthier World by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets. By combining technological insight with world-class manufacturing, scientific expertise and process excellence, we help our customers to deliver new and innovative medicines that help treat a wide range of diseases. While we work in science, there’s no magic formula to how we do it. Our greatest scientific solution is talented people working together, devising commitment and ideas that help our customers to help people. In exchange, we let our people own their careers. Their ideas, big and small, genuinely improve the world. And that’s the kind of work we want to be part of. Our work makes A Meaningful Difference.
- Website
-
http://www.lonza.com
Externer Link zu Lonza
- Branche
- Arzneimittelherstellung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Basel
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 1897
- Spezialgebiete
- Pharmaceutical ingredients, Bioscience, Biopharmaceuticals, Custom manufacturing, Biotechnology, Life science ingredients, Nutrition, Cell Therapy, Gene Therapy und Capsules
Orte
Beschäftigte von Lonza
-
Peter Harrison
Digital Transformation Director, Operational Improvement, ERP Portfolio planning & Programme Delivery for Finance, HR and Workforce Management…
-
Meredith Brown
-
Sebastian Stenderup
Executive Director - Lonza
-
Xavier Marmasse
Global Category Group Leader at Lonza
Updates
-
Today we celebrate 40 years of industry leadership and bold decision-making which laid the foundation for the Lonza of today. In the early 1980s, Lonza began exploring biotechnology as a new opportunity for innovation and growth, marking a significant shift for a traditional chemicals company. As the need for more complex molecules increased, Lonza kept developing microbial processes to produce them: in 1986, the first 400 liter bioreactor plant went into operation in Visp. Since then, the growth of Lonza’s Microbial business has been driven by its people, who continue to innovate to bring today's therapies to life. #AHealthierWorld #Biologics #Microbial #PharmaceuticalManufacturing #Biotechnology
-
Our team is excited to attend this year’s CPHI 2024 in Milan. Visit our booth 6A2 and learn more how Lonza can support your drug development journey and about our award-winning products and services. Looking forward to seeing you! #CPHI2024 #CPHI2024Milan #OneLonza #CPHIPharmaAward
-
We are honored to announce that our AI-Enabled Route Scouting Service has been selected as the winner of the API Development and Innovation Award, presented at the annual CPHI Pharma Awards in Milan, Italy. Congratulations to the entire Small Molecules team. Simon Wagschal, Aaron Johnson, PhD, Dominique M. Roberge, Jan Vertommen, PhD, David Hall, Hannah McLachlan If you want to learn more about this award-winning offering, meet our colleagues at the CPHI booth 6A2 or click here: https://lnkd.in/dfx7Yb8Z #CPHI #CPHIPharmaAwards #Innovation #CPHIPharmaAwards2024 #CPHIPharmaAwardsWinner #RouteScouting #AI #AIEnabledRouteScouting
-
We're excited to be at the upcoming PDA Universe of Pre-Filled Syringes and Injection Devices Conference. This year we're at booth 908. 👉 And don't miss Flora Felsovalyi's tech talk: "Accelerating Your Vial to PFS Pathway" Tuesday, 22 October 12:40 #LonzaDPS #sterileDrugProduct #patientSafetyFrist
-
"The diversity in the design of ADCs directly translates to a diversity in technologies that are necessary for ensuring product quality, purity, sterility, and compliance with evolving regulatory requirements. Considering the number of processes involved, the manufacture of ADC-based therapies requires significant capital investments, decades of experience, and immense technical expertise across a multitude of platforms and technologies." Pierre Landais, Director of Commercial Development for Drug Product Services at Lonza and Sandro Holzer, Head of Development for Bioconjugates at Lonza, contributed an article to World Pharma Today about how CDMOs can help navigate some of the bottlenecks of ADC manufacturing. Read the full article here: https://lnkd.in/dR6Ars-s #AHealthierWorld #PharmaceuticalManufacturing #ADC #Biologics
-
We are excited to attend American Association of Pharmaceutical Scientists (AAPS) | @aapscomms PharmSci 360 2024 this year in Salt Lake City, UT, from 20 October – 23 October. Stop by our booth #2724, and join us for some insightful presentations by our experts: Partner Session: 📅 21th October 2024, 2:00 - 3:00pm Title: “Sustainable Innovation for Manufacturing Amorphous Solid Dispersions” Speakers: Adi Kaushal, PhD (Technology Head, Bioavailability Enhancement) and Craig Sather, BA (Associate Director, Principal Investigator, CMC) Poster Presentations: 📅 21st October 2024, 10:30 - 11:30am “Comparative Analysis of Co-Processes AVICEL DG vs Individual Microcrystalline Cellulose and Anhydrous Di-Calcium Phosphate in Tablet Formulation” Poster presenter: Dr. Ramesh Kenchappa, M.S., (Pharma)., Ph.D., F.I.C (Manager, Formulation) 📅 21st October 2024, 12:30 - 1:30pm “A Comparative Approach in the evaluation and Optimization of Enteric Coating for Tablet Formulation” Poster presenter: Karthikeyan Selvaraj, MS (Research Scientist) 📅 21st October 2024, 2:30 - 3:30pm Title: “Material Sparing Dry Granulation via RoCo Simulation Enables Technical Transfer of SDI-Based Formulations” Poster presenter: Allison DuRoss, PhD (Associate Principal Engineer) 📅 21st October 2024, 3:30 - 4:30pm “Innovative Moisture Activated Dry Granulation (MADG) with Mesoporous Silica vs Wet Granulation: A Comparative Study” Poster presenter: Dr. Ramesh Kenchappa, M.S., (Pharma)., Ph.D., F.I.C (Manager, Formulation) 📅 23rd October 2024, 10:30 - 11:30am Title: “Early-Phase Form Screening of Solubility-Limited Drugs Via In-Vitro Characterization and In-Silico Modeling” Poster presenter: Arianna Nejely, BS (Scientist, Product Development) The Lonza team looks forward to meeting you at AAPS PharmSci 360 2024! #LonzaSM #WeWorkAsOne #SmallMolecules #AAPS #PharmSci360
-
Next week, our Cell & Gene leaders will travel to the Alliance for Regenerative Medicine’s Meeting on the MESA and play an active role focused on accelerating the successful commercialization of Cell & Gene Therapies globally. If you are attending, don't miss the panel discussion on "Investing in Cell and Gene Therapy – Current Global Market Trends", joined by Thomas Fellner, our Vice President, Global Head of Operations for Cell & Gene Technologies. We’d welcome the opportunity to sit down with you and discuss bringing your science to market. Please reach out to us using the Partnering App or through our website (https://lnkd.in/eMYDVTmU) to meet with one of our team on-site. #RealizingPotentialTogether #commercialization #GeneTherapy #CellTherapy
-
Lonza hat dies direkt geteilt
One of the most important goals of genetic engineering, especially within the biopharmaceutical industry space, is the ability to produce therapeutic proteins. Over the years spent working in this field, Pichia pastoris has become my personal favorite expression system, mainly due to its versatility across scales and the appropriate folding and secretion of recombinant proteins expressed in this system, and their ease of purification. Lonza has developed the XS® Pichia Expression System to help accommodate industry trends, eliminate production bottlenecks, align downstream processing, and drive breakthroughs into the clinic. Learn more about P. pastoris and its use at Lonza in my new blog. #PichiaPastoris #Recombinant #Lonza #PharmaceuticalIndustry #RandDBlog
-
Today, we completed our acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 billion. With a total bioreactor capacity of around 330,000 liters, the Vacaville facility significantly extends our mammalian manufacturing footprint in the US, the world’s largest pharmaceutical market. We extend a warm welcome to our new colleagues in Vacaville as the site joins our global Biologics manufacturing network. #AHealthierWorld #Acquisition #Growth #Biologics
Verbundene Seiten
-
Lonza BioResearch Solutions
Biotechnologieforschung
Walkersville, Maryland
-
Lonza Capsules & Health Ingredients
Arzneimittelherstellung
Morristown, New Jersey
-
Lonza Testing Solutions
Biotechnologieforschung
Walkersville, Maryland
-
Lonza MODA®- Informatics Solutions for QC & Manufacturing
Softwareentwicklung
Basel, BS
Ähnliche Seiten
Finanzierung
Letzte Runde
Fremdkapital nach Börsengang444.795.339,00 $